510 Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, With or Without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation
Titel:
510 Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, With or Without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation
Auteur:
Malik, Asifa Bueso-Ramos, Carlos Faderl, Stefan Estey, Eli O'Brien, Susan Fernandez, Michael Nguyen, Martin Koller, Charles Freireich, Emil Beran, Miloslav Pierce, Sherry Cortes, Jorge Kantarjian, Hagop Ravandi, Farhad